For PTCL-NOS, CCNA2 (85.7% vs. 0%; HR 25.193, 95% CI 3.140–202.120, p < 0.002), TOP2A (85.7% vs. 0%; HR 17.455, 95% CI 2.191-139.039, p = 0.007), CHEK1 (75% vs. 0%; HR 9.490, 95% CI 2.035–44.252, p = 0.004), and IKBkB (49.1% vs. 9.1%; HR 3.763, 95% CI 1.255–11.281, p = 0.018) ≥ median were associated with worse 3-year OS. Here, CHEK1 is linked to mature T-cell and NK-cell non-Hodgkin lymphoma.